Adam D Cohen Selected Research

belantamab mafodotin

12/2023	Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
11/2021	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
10/2020	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
1/2020	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
12/2019	Myeloma: next generation immunotherapy.
1/2019	Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
12/2018	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adam D Cohen Research Topics

Disease

51	Multiple Myeloma 05/2024 - 01/2013
28	Neoplasms (Cancer) 05/2024 - 05/2006
6	Immunoglobulin Light-chain Amyloidosis 05/2024 - 10/2007
6	Melanoma (Melanoma, Malignant) 01/2013 - 01/2005
5	Disease Progression 01/2022 - 01/2020
5	Experimental Melanoma 10/2021 - 05/2006
4	Residual Neoplasm 01/2023 - 12/2019
3	Leukemia 05/2024 - 12/2013
3	Amyloidosis 10/2023 - 10/2007
2	Monoclonal Gammopathy of Undetermined Significance 05/2024 - 01/2024
2	Infections 03/2024 - 02/2022
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2024 - 10/2016
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2024 - 10/2016
2	Cytokine Release Syndrome 12/2023 - 01/2018
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2023 - 09/2006
2	Bites and Stings (Sting) 01/2020 - 12/2019
2	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 10/2016
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2015 - 10/2012
1	cell-associated neurotoxicity 12/2023
1	Atypical Hemolytic Uremic Syndrome 11/2021
1	Cytopenia 01/2019
1	Inflammation (Inflammations) 01/2019
1	Castleman Disease (Castleman's Disease) 01/2019
1	Primary Myelofibrosis (Myelosclerosis) 01/2019
1	Fever (Fevers) 01/2019
1	Edema (Dropsy) 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Necrosis 12/2018

Drug/Important Bio-Agent (IBA)

17	Chimeric Antigen ReceptorsIBA 01/2024 - 09/2015
15	B-Cell Maturation AntigenIBA 12/2023 - 12/2018
11	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2024 - 12/2018
11	Proteasome InhibitorsIBA 06/2023 - 01/2017
10	Monoclonal AntibodiesIBA 06/2023 - 04/2009
8	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2003
7	Bortezomib (Velcade)FDA Link 05/2024 - 12/2016
7	belantamab mafodotinIBA 12/2023 - 12/2018
7	Proteins (Proteins, Gene)FDA Link 06/2023 - 05/2006
6	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 12/2018
5	Lenalidomide (CC 5013)FDA Link 01/2023 - 09/2015
5	Immunomodulating AgentsIBA 11/2021 - 01/2017
5	AntigensIBA 12/2019 - 09/2006
5	Melphalan (Alkeran)FDA LinkGeneric 01/2019 - 10/2007
5	DNA VaccinesIBA 01/2013 - 01/2005
4	Bispecific AntibodiesIBA 01/2024 - 12/2019
4	carfilzomibIBA 11/2021 - 03/2018
4	VaccinesIBA 01/2020 - 05/2006
4	elotuzumabIBA 10/2019 - 01/2017
4	AutoantigensIBA 01/2013 - 05/2006
4	DNA (Deoxyribonucleic Acid)IBA 09/2006 - 05/2006
3	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 10/2023 - 01/2010
3	Alkylating AgentsIBA 10/2021 - 05/2009
3	AntibodiesIBA 12/2019 - 12/2010
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 06/2006
2	Busulfan (Busulfex)FDA Link 05/2024 - 01/2024
2	Surface Antigens (Surface Antigen)IBA 01/2024 - 01/2017
2	Single-Domain AntibodiesIBA 12/2022 - 01/2021
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021 - 05/2009
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2021 - 04/2009
2	GlucocorticoidsIBA 10/2021 - 04/2009
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
2	Immunoglobulin G (IgG)IBA 10/2019 - 05/2010
2	tisagenlecleucelIBA 01/2018 - 09/2015
2	LigandsIBA 09/2015 - 05/2006
2	Peptides (Polypeptides)IBA 04/2009 - 05/2006
2	EpitopesIBA 04/2009 - 05/2006
2	Monophenol Monooxygenase (Tyrosinase)IBA 04/2009 - 05/2006
1	birtamimabIBA 10/2023
1	Amyloid (Amyloid Fibrils)IBA 10/2023
1	Dihydrotachysterol (AT 10)IBA 01/2023
1	pomalidomideIBA 01/2023
1	Immunoglobulins (Immunoglobulin)IBA 02/2022
1	eculizumab FDA Link 11/2021
1	trans-crotonin (CTN)IBA 10/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Reticulin (Reticular Fiber)IBA 01/2019
1	C-Reactive ProteinIBA 01/2019
1	CytokinesIBA 01/2019
1	Immunologic Factors (Immunomodulators)IBA 12/2018
1	monomethylauristatin FIBA 12/2018
1	Cell Surface ReceptorsIBA 12/2018
1	filanesibIBA 12/2017
1	daratumumabIBA 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2017
1	ixazomibIBA 01/2017
1	tabalumabIBA 12/2016
1	B-Cell Activating FactorIBA 12/2016

Therapy/Procedure

41	Therapeutics 03/2024 - 01/2003
8	Immunotherapy 01/2024 - 12/2010
8	Stem Cell Transplantation 01/2022 - 09/2006
3	Drug Therapy (Chemotherapy) 06/2023 - 01/2003
2	Aftercare (After-Treatment) 06/2023 - 03/2023
2	Salvage Therapy 01/2013 - 10/2012
2	Ligation 05/2010 - 05/2006
1	Blood Component Removal (Apheresis) 12/2023
1	Radiotherapy 11/2023
1	Transplantation 01/2022
1	Intravenous Infusions 01/2020
1	Precision Medicine 01/2019